The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 210 results:
Author Title [ Type(Desc)] Year
Filters: Author is Athyros, Vasilios G  [Clear All Filters]
Journal Article
Tziomalos, K., Athyros V. G., & Karagiannis A. (2015).  Cardiovascular Risk in Middle East Populations: A Call to Action.. Angiology. 66(9), 801-2.
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Cardiovascular risk reduction with combination of anti-atherosclerotic medications in younger and older patients.. Curr Med Res Opin. 29(7), 791-2.
Stavropoulos, K., Imprialos K. P., Doumas M., & Athyros V. G. (2018).  Carotid intima-media thickness as a target-organ damage and treatment-target: Need for a major revision?. J Clin Hypertens (Greenwich). 20(2), 255-257.
Theocharidou, E., Gossios T. D., Giouleme O., Athyros V. G., & Karagiannis A. (2014).  Carotid intima-media thickness in patients with inflammatory bowel disease: a systematic review.. Angiology. 65(4), 284-93.
Rizos, C. V., Elisaf M. S., Skoumas I., Tziomalos K., Kotsis V., Rallidis L., et al. (2018).  Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH).. Atherosclerosis. 277, 308-313.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2014).  Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview.. Curr Vasc Pharmacol. 12(4), 627-41.
Athyros, V. G., Kakafika A., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2008).  Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended?. Expert Opin Investig Drugs. 17(4), 445-9.
Athyros, V. G., Gossios T. D., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2012).  The clinical benefit of implementing guidelines in cardiovascular disease prevention in real world settings.. Arch Med Sci. 8(1), 6-10.
Anagnostis, P., Athyros V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2009).  Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis.. J Clin Endocrinol Metab. 94(8), 2692-701.
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Cold temperature and cardiovascular mortality.. Circ J. 77(11), 2846.
Tziomalos, K., Athyros V. G., & Mikhailidis D. P. (2009).  Colesevelam improves glycemic control and lipid management in inadequately controlled type 2 diabetes mellitus.. Nat Clin Pract Endocrinol Metab. 5(1), 16-7.
Doumas, M., Imprialos Κ., Stavropoulos K., Reklou A., Sachinidis A., & Athyros V. G. (2018).  Combination of SGLT-2 inhibitors and GLP-1 receptor agonists: potential benefits in surrogate and hard endpoints.. Curr Pharm Des.
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Comment on: Novel therapeutic targets for non-alcoholic fatty liver disease.. Expert Opin Ther Targets. 17(7), 861-2.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2013).  Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property".. Dig Liver Dis. 45(1), 82-3.
Anagnostis, P., Adamidou F., Slavakis A., Polyzos S. A., Selalmatzidou D., Panagiotou A., et al. (2014).  Comparative Effect of Atorvastatin and Rosuvastatin on 25-hydroxy-Vitamin D Levels in Non-diabetic Patients with Dyslipidaemia: A Prospective Randomized Open-label Pilot Study.. Open Cardiovasc Med J. 8, 55-60.
Athyros, V. G., Ganotakis E. S., Tziomalos K., Papageorgiou A. A., Anagnostis P., Griva T., et al. (2010).  Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population.. Curr Med Res Opin. 26(3), 713-9.
Karagiannis, A., Athyros V. G., & Mikhailidis D. P. (2009).  A comparison of the aldosterone-blocking agents eplerenone and spironolactone.. Clin Cardiol. 32(4), 230.
Athyros, V. G., Mitsiou E. K., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2010).  Concurrent blood pressure, glycemic and lipid control for the prevention of vascular complications of type II diabetes mellitus: a long overdue objective?. Curr Vasc Pharmacol. 8(1), 1-4.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2015).  Contrast-Induced Nephropathy: An "All or None" Phenomenon?. Angiology. 66(6), 508-13.
Athyros, V. G., Kakafika A. I., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2008).  CORONA, statins, and heart failure: who lost the crown?. Angiology. 59(1), 5-8.
Imprialos, K. P., Boutari C., Stavropoulos K., Doumas M., Athyros V. G., & Karagiannis A. I. (2016).  Current challenges in antihypertensive treatment in the elderly.. Pol Arch Med Wewn. 126(7-8), 540-51.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2011).  Current treatment for nonalcoholic fatty liver disease.. Expert Opin Pharmacother. 12(13), 2141-2; author reply 2142.
Katsiki, N., Athyros V. G., & Mikhailidis D. P. (2011).  The DEFINE study: a bright future for CETP inhibitors?. Expert Opin Investig Drugs. 20(3), 311-4.
Athyros, V. G., Doumas M., Imprialos K. P., Stavropoulos K., Georgianou E., Katsimardou A., et al. (2018).  Diabetes and lipid metabolism.. Hormones (Athens). 17(1), 61-67.
Anagnostis, P., Paschou S. A., Goulis D. G., Athyros V. G., & Karagiannis A. (2018).  Dietary management of dyslipidaemias. Is there any evidence for cardiovascular benefit?. Maturitas. 108, 45-52.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.